- Home
- FHN vs BMRN Comparison
FHN vs BMRN Comparison
Compare FHN & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHN
- BMRN
- Stock Information
- Founded
- FHN 1864
- BMRN 1996
- Country
- FHN United States
- BMRN United States
- Employees
- FHN N/A
- BMRN N/A
- Industry
- FHN Major Banks
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- FHN Finance
- BMRN Health Care
- Exchange
- FHN Nasdaq
- BMRN Nasdaq
- Market Cap
- FHN 11.0B
- BMRN 10.0B
- IPO Year
- FHN N/A
- BMRN 1999
- Fundamental
- Price
- FHN $21.49
- BMRN $51.52
- Analyst Decision
- FHN Buy
- BMRN Buy
- Analyst Count
- FHN 20
- BMRN 19
- Target Price
- FHN $24.10
- BMRN $90.26
- AVG Volume (30 Days)
- FHN 15.5M
- BMRN 2.8M
- Earning Date
- FHN 10-15-2025
- BMRN 10-27-2025
- Dividend Yield
- FHN 2.79%
- BMRN N/A
- EPS Growth
- FHN 19.36
- BMRN 59.53
- EPS
- FHN 1.64
- BMRN 2.68
- Revenue
- FHN $3,185,000,000.00
- BMRN $3,094,001,000.00
- Revenue This Year
- FHN $12.50
- BMRN $13.32
- Revenue Next Year
- FHN $2.81
- BMRN $7.51
- P/E Ratio
- FHN $13.08
- BMRN $19.20
- Revenue Growth
- FHN 3.75
- BMRN 12.39
- 52 Week Low
- FHN $15.19
- BMRN $50.76
- 52 Week High
- FHN $23.70
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- FHN 49.88
- BMRN 40.53
- Support Level
- FHN $20.95
- BMRN $51.80
- Resistance Level
- FHN $21.70
- BMRN $53.49
- Average True Range (ATR)
- FHN 0.47
- BMRN 1.84
- MACD
- FHN 0.11
- BMRN -0.08
- Stochastic Oscillator
- FHN 83.00
- BMRN 12.58
About FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.